2026 Q2 -tulosraportti
UUTTA
Tänään
‧48 min
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 25.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 26.8. | ||
2026 Q1 -tulosraportti 27.5. | ||
2025 Q4 -tulosraportti 25.2. | ||
2025 Q3 -tulosraportti 24.11.2025 | ||
2025 Q2 -tulosraportti 27.8.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·44 min sittenI actually view my investment in Nykode as a long-term option towards 2029. I don't need to know when or if a partnership agreement will come. The interesting thing is that Nykode has several shots on goal: VB10.NEO and partnering, Abili-T-data, NeoSELECT/data and ASIT. With a positive final outcome in the tax case, they will also get 325 mill. + interest back and runway until 2029. For me, the case is therefore about something quite simple: I believe the probability that at least one of these options truly hits before capital becomes a problem, is greater than what today's valuation suggests. And in biotech, one direct hit can be enough.
Precise and very good 👍 / if we had been back to before 2007 (DMA), the stock would probably have been much higher.
·2 t sittenThe article is from today, before the tax news of course, but I thought it was good reading.
·2 t sitten · MuokattuA strange trading pattern, to say the least, we have witnessed today; first, we experience massive sales on falling prices after a very positive and promising presentation. Most things are set for a good development, and we find that several analysts and strategists point to "health" as one of the few sectors to be ahead. Next comes the news that tax matters are as good as settled; another writer has stated that 98% of the committee's recommendations are followed, so it seems reasonably certain that NYKD will prevail and can extend its runway until 2029. This will most likely save shareholders at least one funding round with associated dilution. That the sum of this day would be a fall of 0.86% was probably something few had envisioned, but I think this clears the ground for a strong upturn as soon as those who have kept the price down today are finished with their sell-off.Completely hopeless. I think it was short NYKD vs. long CRNA in a hodgepodge of an algo-hell.
·3 t sittenI read that they can be financed until 2029 if they receive these 325 million + interest, otherwise they are financed until 2028. Do they burn through 325+ million annually? That is a lot of money ..
·3 t sittenMr Gemini is at least positive: If Nykode Therapeutics receives final approval and gets 325 million kroner plus interest, the adjusted Price/Book value (P/B) will fall to around 1.0. This is because the company's book equity (the accounting value) increases significantly when this money is added to the balance sheet. A P/B value of around 1.0 practically means that the market values the company equally with the pure cash and assets on paper, which is very low for a biotech company at this stage. This is how the tax money affects the calculation: Today's book equity: Is just under 1.15 billion kroner based on market horizons and current multiples. New book equity: Upon a payout of 325 million kroner (plus estimated interest that can raise the sum up to 350 million), the book equity increases to approx. 1.49 billion kroner. Market value: Nykode's market value on Oslo Børs is today also around 1.49 billion kroner (given a share price of around 4.56 NOK and 326.55 million shares). When P/B falls towards 1.0, it means that you as an investor pay minimal "premium" for everything else Nykode owns. In other words, you get the entire technological platform, all patents, and the value of the ongoing clinical studies (such as cancer vaccines) almost "for free" with the purchase, because the share price is largely covered by the pure cash in the company.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q2 -tulosraportti
UUTTA
Tänään
‧48 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·44 min sittenI actually view my investment in Nykode as a long-term option towards 2029. I don't need to know when or if a partnership agreement will come. The interesting thing is that Nykode has several shots on goal: VB10.NEO and partnering, Abili-T-data, NeoSELECT/data and ASIT. With a positive final outcome in the tax case, they will also get 325 mill. + interest back and runway until 2029. For me, the case is therefore about something quite simple: I believe the probability that at least one of these options truly hits before capital becomes a problem, is greater than what today's valuation suggests. And in biotech, one direct hit can be enough.Precise and very good 👍 / if we had been back to before 2007 (DMA), the stock would probably have been much higher.
- ·2 t sittenThe article is from today, before the tax news of course, but I thought it was good reading.
- ·2 t sitten · MuokattuA strange trading pattern, to say the least, we have witnessed today; first, we experience massive sales on falling prices after a very positive and promising presentation. Most things are set for a good development, and we find that several analysts and strategists point to "health" as one of the few sectors to be ahead. Next comes the news that tax matters are as good as settled; another writer has stated that 98% of the committee's recommendations are followed, so it seems reasonably certain that NYKD will prevail and can extend its runway until 2029. This will most likely save shareholders at least one funding round with associated dilution. That the sum of this day would be a fall of 0.86% was probably something few had envisioned, but I think this clears the ground for a strong upturn as soon as those who have kept the price down today are finished with their sell-off.Completely hopeless. I think it was short NYKD vs. long CRNA in a hodgepodge of an algo-hell.
- ·3 t sittenI read that they can be financed until 2029 if they receive these 325 million + interest, otherwise they are financed until 2028. Do they burn through 325+ million annually? That is a lot of money ..
- ·3 t sittenMr Gemini is at least positive: If Nykode Therapeutics receives final approval and gets 325 million kroner plus interest, the adjusted Price/Book value (P/B) will fall to around 1.0. This is because the company's book equity (the accounting value) increases significantly when this money is added to the balance sheet. A P/B value of around 1.0 practically means that the market values the company equally with the pure cash and assets on paper, which is very low for a biotech company at this stage. This is how the tax money affects the calculation: Today's book equity: Is just under 1.15 billion kroner based on market horizons and current multiples. New book equity: Upon a payout of 325 million kroner (plus estimated interest that can raise the sum up to 350 million), the book equity increases to approx. 1.49 billion kroner. Market value: Nykode's market value on Oslo Børs is today also around 1.49 billion kroner (given a share price of around 4.56 NOK and 326.55 million shares). When P/B falls towards 1.0, it means that you as an investor pay minimal "premium" for everything else Nykode owns. In other words, you get the entire technological platform, all patents, and the value of the ongoing clinical studies (such as cancer vaccines) almost "for free" with the purchase, because the share price is largely covered by the pure cash in the company.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 25.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 26.8. | ||
2026 Q1 -tulosraportti 27.5. | ||
2025 Q4 -tulosraportti 25.2. | ||
2025 Q3 -tulosraportti 24.11.2025 | ||
2025 Q2 -tulosraportti 27.8.2025 |
2026 Q2 -tulosraportti
UUTTA
Tänään
‧48 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 25.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 26.8. | ||
2026 Q1 -tulosraportti 27.5. | ||
2025 Q4 -tulosraportti 25.2. | ||
2025 Q3 -tulosraportti 24.11.2025 | ||
2025 Q2 -tulosraportti 27.8.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·44 min sittenI actually view my investment in Nykode as a long-term option towards 2029. I don't need to know when or if a partnership agreement will come. The interesting thing is that Nykode has several shots on goal: VB10.NEO and partnering, Abili-T-data, NeoSELECT/data and ASIT. With a positive final outcome in the tax case, they will also get 325 mill. + interest back and runway until 2029. For me, the case is therefore about something quite simple: I believe the probability that at least one of these options truly hits before capital becomes a problem, is greater than what today's valuation suggests. And in biotech, one direct hit can be enough.Precise and very good 👍 / if we had been back to before 2007 (DMA), the stock would probably have been much higher.
- ·2 t sittenThe article is from today, before the tax news of course, but I thought it was good reading.
- ·2 t sitten · MuokattuA strange trading pattern, to say the least, we have witnessed today; first, we experience massive sales on falling prices after a very positive and promising presentation. Most things are set for a good development, and we find that several analysts and strategists point to "health" as one of the few sectors to be ahead. Next comes the news that tax matters are as good as settled; another writer has stated that 98% of the committee's recommendations are followed, so it seems reasonably certain that NYKD will prevail and can extend its runway until 2029. This will most likely save shareholders at least one funding round with associated dilution. That the sum of this day would be a fall of 0.86% was probably something few had envisioned, but I think this clears the ground for a strong upturn as soon as those who have kept the price down today are finished with their sell-off.Completely hopeless. I think it was short NYKD vs. long CRNA in a hodgepodge of an algo-hell.
- ·3 t sittenI read that they can be financed until 2029 if they receive these 325 million + interest, otherwise they are financed until 2028. Do they burn through 325+ million annually? That is a lot of money ..
- ·3 t sittenMr Gemini is at least positive: If Nykode Therapeutics receives final approval and gets 325 million kroner plus interest, the adjusted Price/Book value (P/B) will fall to around 1.0. This is because the company's book equity (the accounting value) increases significantly when this money is added to the balance sheet. A P/B value of around 1.0 practically means that the market values the company equally with the pure cash and assets on paper, which is very low for a biotech company at this stage. This is how the tax money affects the calculation: Today's book equity: Is just under 1.15 billion kroner based on market horizons and current multiples. New book equity: Upon a payout of 325 million kroner (plus estimated interest that can raise the sum up to 350 million), the book equity increases to approx. 1.49 billion kroner. Market value: Nykode's market value on Oslo Børs is today also around 1.49 billion kroner (given a share price of around 4.56 NOK and 326.55 million shares). When P/B falls towards 1.0, it means that you as an investor pay minimal "premium" for everything else Nykode owns. In other words, you get the entire technological platform, all patents, and the value of the ongoing clinical studies (such as cancer vaccines) almost "for free" with the purchase, because the share price is largely covered by the pure cash in the company.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt